The present invention concerns the compound aprocitentan, {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-sulfamide:and its use as endothelin receptor antagonist, in combination with an SGLT-2 inhibitor. The invention further relates to pharmaceutical compositions comprising aprocitentan in combination with said SGLT-2 inhibitor. The invention further relates to such pharmaceutical compositions comprising crystalline forms of aprocitentan.本發明係關於化合物阿普羅西替坦(aprocitentan) {5-(4-溴-苯基)-6-[2-(5-溴-嘧啶-2-基氧基)-乙氧基]-嘧啶-4-基}-磺醯胺:及其作為內皮素受體拮抗劑與SGLT-2抑制劑組合之用途。本發明進一步係關於包含阿普羅西替坦與該SGLT-2抑制劑組合之醫藥組合物。本發明進一步係關於包含阿普羅西替坦之結晶形式之該等醫藥組合物。